Back to search results

Atezolizumab+Bevacizumab+SBRT in Unresectable HCC

Abroad (travel likely)RecruitingPHASE1

Conditions

Unresectable Hepatocellular Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

    Contact: Study coordinator (Jennifer Y Wo, MD) · jwo@mgh.harvard.edu · (617) 726-6050
    Contact: Principal Investigator (Jennifer Y Wo, MD)

  • Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

    Contact: Study coordinator (Matthew Abrams, MD) · mabrams2@bidmc.harvard.edu · 617-667-2345
    Contact: Principal Investigator (Matthew Abrams, MD)

  • Dana-Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Harvey Mamon, MD, PhD) · HMAMON@PARTNERS.ORG · (617) 732-8821
    Contact: Principal Investigator (Harvey Mamon, MD, PhD)
Study leads

  • Jennifer Y Wo, MD

    Principal Investigator

    Massachusetts General Hospital

View source on ClinicalTrials.gov(opens in a new tab)